Current trials: Burkitt Lymphoma

B-NHL 2013Recruiting

A study on the treatment protocol of the NHL-BFM and NOPHO Studien GruppenT for mature B-cell non-Hodgkin lymphoma and Burkitt leukemia in children and adolescents (B-NHL 2013)

Lymphomas and leukemias are malignant diseases of the blood cells that vary greatly in their presentation and prognosis. The aggressive subtypes spread rapidly and usually require prompt treatment, most often a combination of chemotherapy and an antibody. The goal of the B-NHL 2013 study is to investigate the efficacy of the antibody rituximab in addition to standard chemotherapy for aggressive mature B-cell non-Hodgkin lymphomas (B-NHL) and Burkitt leukemia (B-AL), and to compare it with the treatment currently in use. Patients who have been newly diagnosed with these diseases and are under 18 years of age are eligible to participate in the study.

0–18 years · First line · Phase III

GMALL RegistryRecruiting

GMALL Registry Study on Acute Lymphoblastic Leukemia (ALL): Prospective Collection of Data on Diagnosis, Treatment, Course of the Disease, and Biological Samples in Adult ALL Patients

Acute lymphoblastic leukemia (ALL) is a malignant disease of the lymphatic system that is typically treated according to a fixed treatment protocol, often the GMALL protocol (German Multicenter Study Group for Adult ALL). The GMALL registry study collects data on the diagnosis, treatment, and outcomes of patients, as well as biological samples. No new drugs or therapies are being tested in this study. Women and men aged 18 and older with ALL or related forms of ALL who are being treated according to a GMALL treatment protocol are eligible to participate in the study.

18 years and older

iMATRIX GLORecruiting

A study of the drug Glofitamab as monotherapy and in combination with standard therapy in children and young adults with relapsed or refractory mature B-cell non-Hodgkin lymphoma

B-cell non-Hodgkin lymphoma (NHL) is an umbrella term for cancers of the lymphatic system. These can occur in both adults and children. The standard treatment consists of immunochemotherapy. Glofitamab is a newly approved antibody that can both bind to and destroy cancer cells while simultaneously stimulating the immune system (bispecific). The goal of the iMATRIX GLO study is to investigate the safety and efficacy of glofitamab as monotherapy and in combination with immunochemotherapy. Children, adolescents, and young adults aged 6 months to 18 or 30 years with NHL are eligible to participate in the study if the disease does not respond to standard therapy (refractory) or has become active again after treatment (relapse).

6–30 years · Relapsed / refractory · Phase I/II

M20-429Active, not recruiting

Study of Adverse Events and Changes in Disease Status in Pediatric Participants (and Young Adults Aged 18–25) With Relapsed/Refractory Aggressive Mature B-Cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

So-called mature B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma, are malignant diseases of the lymphatic system that can also occur in children. If standard therapy is ineffective (refractory) or the disease returns (recurrence), further treatments are necessary. The aim of this study is to investigate the safety and efficacy of epcoritamab—an antibody that targets cancer cells while simultaneously strengthening the body’s own immune system (bispecific)—in this situation. Patients between the ages of 1 and 25 with DLBCL, Burkitt lymphoma, or other mature B-cell lymphomas are eligible to participate in this study.

1–25 years · Relapsed / refractory · Phase I

MK-9999-01A/LIGHTBEAM-U01Recruiting

Substudy to Evaluate the Drug Zilovertamab Vedotin in Children and Young Adults with Certain Forms of Blood Cancer or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

In certain types of cancer affecting children and young adults—including forms of blood and lymph node cancer—the disease often returns (recurrence) or no longer responds adequately to current treatment (refractory) despite intensive treatment. The new anticancer drug zilovertamab vedotin is designed to specifically bind to cancer cells and enable their destruction. The goal of the LIGHTBEAM-U01 study is to investigate the safety and efficacy of this new anticancer drug, zilovertamab vedotin. Children and young adults aged 6 months to 25 years with certain types of cancer, including B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, neuroblastoma, and Ewing sarcoma. The cancer must have either returned or no longer be responding to other treatments.

6–25 years · Relapsed / refractory · Phase I/II